Hims & Hers Prices Upsized $350M Convertible Notes at 32.5% Premium for Growth

summarizeSummary

Hims & Hers Health, Inc. priced an upsized $350 million offering of 0.00% Convertible Senior Notes due 2032, with an initial conversion price representing a 32.5% premium over its recent stock price. The proceeds will fund international expansion, including the Eucalyptus acquisition, and AI-driven platform investments.

check_boxKey Events

• Upsized Convertible Senior Notes Offering Priced

  Hims & Hers priced an upsized private offering of $350 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032. Initial purchasers have an option to buy an additional $52.5 million.

• Favorable Pricing Terms

  The notes bear 0.00% interest and have an initial conversion price of approximately $29.53 per share, representing a 32.5% premium over the last reported stock price of $22.29 on May 18, 2026.

• Strategic Use of Proceeds

  Net proceeds of approximately $338.5 million (or $389.5 million if the option is fully exercised) will be used to fund international expansion, including the Eucalyptus acquisition, and to invest in technology, fulfillment infrastructure, and AI capabilities.

• Dilution Mitigation Measures

  The company entered into capped call transactions, with an initial cap price of approximately $50.15 per share (125% premium), to reduce potential dilution upon conversion of the notes.

auto_awesomeAnalysis

Hims & Hers Health, Inc. has secured significant capital through an upsized convertible notes offering. The favorable terms, including 0.00% interest and a substantial 32.5% conversion premium, indicate strong institutional demand and confidence in the company's future. This financing provides crucial flexibility to execute on its international expansion strategy, including the previously announced Eucalyptus acquisition, and to accelerate investments in AI and technology, which are key drivers for future growth, especially following a Q1 net loss.